Ex-FDA officials say RFK Jr. is mischaracterizing their work as he looks to reverse peptide ban

Key Points:

• Nearly three years after the FDA deemed 19 peptide drugs unsafe for compounding pharmacies due to safety concerns, Health and Human Services Secretary Robert F. Kennedy Jr. is poised to reverse this stance despite limited clinical evidence supporting their safety or effectiveness.
• Kennedy argues the FDA acted illegally in 2023 by banning these peptides without clear safety signals, but former FDA officials counter that the decision was based on documented safety risks and regulatory requirements to assess both safety and efficacy.
• The demand for peptides has surged among fitness and longevity enthusiasts, fueling a gray market where unregulated products are sold, sometimes leading to serious health incidents, such as two women falling critically ill after peptide injections at a conference.
• The FDA’s regulatory process for compounding pharmacies centers on the "bulks list," which categorizes substances allowed for compounding; the 19 peptides were placed in the unsafe Category 2 due to risks like immune reactions and lack of sufficient human data.
• Industry groups advocate for easing restrictions to allow compounding pharmacies to dispense peptides, citing safety advantages over the gray market, but experts warn that bypassing rigorous clinical trials could compromise public health and undermine drug approval standards.